članak: 1 od 1  
Acta medica Medianae
2002, vol. 41, br. 3, str. 45-53
jezik rada: srpski
pregledni članak
Insulinska terapija danas
Klinički centar Niš

Sažetak

Podela insulina po dužini delovanja polako postaje deplasirana-neophodno je primamo govoriti o režimima insulinske terapije. Intenzivirana insulinska terapija po tipu multipnih dnevnih injekcija insulina postaje neporečivi standard. Napredak u "proteinskom inženjeringu" sa stvaranjem širokog opsega insulinskih analoga omogućuje da se ide u susret modernoj dijabetologiji i konceptu stroge individualizacije insulinske terapije. Iskustvo postaje obrazac u stvaranju dve postojeće formule insulinskih "kratkih" analoga HUMALAG sa zamenom mesta prolina i lizina na mestima 28 i 29, i NOVORAPID sa aspartičnom kiselinom na 28 mestu B lanca. Noviji dugodelujući analozi nastali su aminokiselinskim promenama sa glicinskom reziduom na poziciji A21 i dva ariginina dodata na pozicije B31 i B32 - insulin "glargin" - LANTUS. Razvoj kratko i dugodelujućih analoga nametnuo je logičnu potrebu formulisanja i "novih" fiksnih insulinskih kombinacija. Nove kombinacije čine dve vrste aktuelnih insulina: brzodelujući analozi tipa aspart ili listroinsulin i protaminom retardiranih preparata - neutralni protamin listroinsulin. Načinjene su tri vrste kombinacija.

Ključne reči

kratkodelujući analozi; dugodelujući analozi; fiksne insulinske kombinacije sa analozima

Reference

Colombel, A., Murat, A., Krempf, M., Kuchly-Anton, B., Charbonnel, B. (1999) Improvement of blood glucose control in Type 1 diabetic patients treated with lispro and multiple NPH injections. Diabet Med, 16(4): 319-24
Dea, M.K., Hamilton-Wessler, M., Ader, M., i dr. (1998) Compartmental modeling of longacting insulin analogue NN304 in vivo. Internat. Diab., Mon., 10, A15-A14
del Sindaco, P., Ciofetta, M., Lalli, C., Perriello, G., Pampanelli, S., Torlone, E., Brunetti, P., Bolli, G.B. (1998) Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: Importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabet Med, 15(7): 592-600
Gammeltoft, S., Hnasen, B.F., Dideriksen, L., i dr. (1999) Insulin aspart: A novel rapid acting human insulin analogue. Expert Opin Investig Drugs, 8, 1431 -1442
Gillies, P.S., Figgitt, D.P., Lamb, H.M. (2000) Insulin glargine. Drugs, 59(2): 253-60; di
Heinemann, L. (1999) Hypoglycemia and insulin analogues: Is there a reduction in the incidence?. J Diabetes Complications, 13(2): 105-14
Heise, T., Weyer, C., Serwas, A., Heinrichs, S., Osinga, J., Roach, P., Woodworth, J., Gudat, U., Heinemann, L. (1998) Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care, 21(5): 800-3
Hermansen, K., Madsbad, S., Koelendorf, K., i dr. (2001) Stronger meal-related effect of biphasic insulin aspart 30 compared to insulin lispro mix 25. u: Annual Meeting of EASD, Glasgow, Oral presentation 54, session 9
Home, P. (1999) Insulin glargine: The first clinically useful extended-acting insulin in Half a century. Expert Opin Investig Drugs, 8, 307-314
Janssen, M.M., Snoek, F.J., Masurel, N., Hoogma, R.P., Deville, W.L., Popp-Snijders, C., Heine, R.J. (2000) Optimized basal-bolus therapy using a fixed mixture of 75% lispro and 25% NPL insulin in type 1 diabetes patients: No favorable effects on glycemic control, physiological responses to hypoglycemia, well-being, or treatment satisfaction. Diabetes Care, 23(5): 629-33
Kurtzhals, P., Schaffer, L., Sorensen, A., Kristensen, C., Jonassen, I., Schmid, C., Trub, T. (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes, 49(6): 999-1005
Mudaliar, S.R., Lindberg, F.A., Joyce, M., Beerdsen, P., Strange, P., Lin, A., Henry, R.R. (1999) Insulin aspart (B28 asp-insulin): A fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care, 22(9): 1501-6
Puttagunta, A.L., Toth, E.L. (1998) Insulin lispro (Humalog), the first marketed insulin analogue: Indications, contraindications and need for further study. CMAJ, 158(4): 506-11
Raskin, P., Riis, A., Guthrie, R.A., Leiter, L., Jovanović, L. (2000) Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care, 23(5): 583-8
Renner, R., Pfutzner, A., Trautmann, M., Harzer, O., Sauter, K., Landgraf, R. (1999) Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. Diabetes Care, 22(5): 784-8
Roach, P., Yue, L., Arora, V. (1999) Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group. Diabetes Care, 22(8): 1258-61